Open AccessThe Influence of an Elevated Production of Extracellular Enveloped Virions of the Vaccinia Virus on Its Properties in Infected Mice
Author(s) -
С. Н. Щелкунов,
S. N. Yakubitskiy,
Tatiana Bauer,
А. А. Сергеев,
А. С. Кабанов,
L. E. Bulichev,
I. A. Yurganova,
Dmitry Odnoshevskiy,
И. В. Колосова,
S. A. Pyankov,
О. С. Таранов
Publication year - 2020
Publication title -
acta naturae
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 26
ISSN - 2075-8251
DOI - 10.32607/actanaturae.10972
Subject(s) - vaccinia , virology , smallpox vaccine , immunogenicity , virulence , orthopoxvirus , virus , attenuated vaccine , smallpox , biology , microbiology and biotechnology , vaccination , recombinant dna , antibody , gene , immunology , genetics
The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulence and immunogenicity of VACV. The research subject was the LIVP strain, which is used in Russia for smallpox vaccination. Two point mutations causing an elevated production of EEVs compared with the parental LIVP strain were inserted into the sequence of the VACV A34R gene. The created mutant LIVP-A34R strain showed lower neurovirulence in an intracerebral injection test and elevated antibody production in the intradermal injection method. This VACV variant can be a promising platform for developing an attenuated, highly immunogenic vaccine against smallpox and other orthopoxvirus infections. It can also be used as a vector for designing live-attenuated recombinant polyvalent vaccines against various infectious diseases.